Safety and Preliminary Efficacy Results of a Novel Mesenchymal Stromal Cell Therapy in Diabetic Kidney Disease: The Multicenter, Randomized, Placebo-Controlled, Phase-1b/2a NEPHSTROM Clinical Trial — Matthew D. Griffin (2022) | RDL Network
Safety and Preliminary Efficacy Results of a Novel Mesenchymal Stromal Cell Therapy in Diabetic Kidney Disease: The Multicenter, Randomized, Placebo-Controlled, Phase-1b/2a NEPHSTROM Clinical Trial
Norberto Perico, Giuseppe Remuzzi, Matthew D. Griffin, Paul Cockwell, Alexander P. Maxwell, Federica Casiraghi, Nadia Rubis, Tobia Peracchi, Alessandro Villa, Marta Todeschini, Fabiola Carrara, Bernadette A. Magee, Piero Ruggenenti, Stefano Rota, Laura Cappelletti, Veronica McInerney, Tomás P. Griffin, Md Nahidul Islam, Martino Introna, Olga Pedrini, Josée Golay, A. Finnerty, Jon Smythe, Willem E. Fibbe, Stephen J. Elliman, Timothy O’Brien
Lauralyn McIntyre, Manoj M. Lalu, Katrina Sullivan, Shirley H. J. Mei, David Moher, Dean Fergusson, Alexander T. Strauss, Duncan J. Stewart, Mazen Jasi, Malcolm Macleod, Brent W. Winston, John Marshall, Keith R. Walley
.webp){kind=small}
Discussion(0)
No comments yet. Be the first to comment.